International Journal of Antimicrobial Agents
Volume 31, Issue 4 , Pages 316-320 , April 2008

European surveillance study on antimicrobial susceptibility of Gram-positive anaerobic cocci

Received 14 November 2007 ,Accepted 15 November 2007.

References 

  1. Song Y, Finegold SM. Peptostreptococcus, Finegoldia, Anaerococcus, Peptoniphilus, Veillonella and other anaerobic cocci. In:  Murray PR,  Baron EJ,  Jorgenssen JH,  Landry ML,  Pfaller MA editor. Manual of clinical microbiology. Washington, DC: ASM Press; 2007;p. 862–888
  2. Murdoch DA. Gram-positive anaerobic cocci. Clin Microbiol Rev. 1998;11:81–120
  3. Jousimies-Somer HR, Summanen P, Citron DM, Baron EJ, Wexler HM, Finegold SM. Wadsworth anaerobic bacteriology manual. 6th ed.. Belmont, CA: Star Publishing Co.; 2002;
  4. Downes J, Wade WG. Peptostreptococcus stomatis sp. nov., isolated from the human oral cavity. Int J Syst Evol Microbiol. 2006;56:751–754
  5. Murdoch DA, Shah HN, Gharbia SE, Rajendram D. Proposal to restrict the genus Peptostreptococcus (Kluyver & van Niel 1936) to Peptostreptococcus anaerobius. Anaerobe. 2000;6:257–260
  6. Murdoch DA, Shah HN. Reclassification of Peptostreptococcus magnus (Prevot 1933) Holdeman and Moore 1972 as Finegoldia magna comb. nov. and Peptostreptococcus micros (Prevot 1933) Smith 1957 as Micromonas micros comb. nov. Anaerobe. 1999;5:555–559
  7. Tindall BJ, Euzeby JP. Proposal of Parvimonas gen. nov. and Quatrionicoccus gen. nov. as replacements for the illegitimate, prokaryotic, generic names Micromonas Murdoch and Shah 2000 and Quadricoccus Maszenan et al. 2002, respectively. Int J Syst Evol Microbiol. 2006;56:2711–2713
  8. Ezaki T, Kawamura Y, Li N, Li ZY, Zhao L, Shu S. Proposal of the genera Anaerococcus gen. nov., Peptoniphilus gen. nov. and Gallicola gen. nov. for members of the genus Peptostreptococcus. Int J Syst Evol Microbiol. 2001;51:1521–1528
  9. Clinical and Laboratory Standards Institute. Methods for antimicrobial susceptibility testing of anaerobic bacteria. 7th ed. Approved standard. Document M11-A7 C. Wayne, PA: CLSI; 2007.
  10. Aldridge KE, Ashcraft D, Cambre K, Pierson CL, Jenkins SG, Rosenblatt JE. Multicenter survey of the changing in vitro antimicrobial susceptibilities of clinical isolates of Bacteroides fragilis group, Prevotella, Fusobacterium, Porphyromonas, and Peptostreptococcus species. Antimicrob Agents Chemother. 2001;45:1238–1243
  11. Brazier JS, Hall V, Morris TE, Gal M, Duerden BI. Antibiotic susceptibilities of Gram-positive anaerobic cocci: results of a sentinel study in England and Wales. J Antimicrob Chemother. 2003;52:224–228
  12. Koeth LM, Good CE, Appelbaum PC, Goldstein EJ, Rodloff AC, Claros M, et al. Surveillance of susceptibility patterns in 1297 European and US anaerobic and capnophilic isolates to co-amoxiclav and five other antimicrobial agents. J Antimicrob Chemother. 2004;53:1039–1044
  13. Mory F, Lozniewski A, Bland S, Sedallian A, Grollier G, Girard-Pipau F, et al. Survey of anaerobic susceptibility patterns: a French multicentre study. Int J Antimicrob Agents. 1998;10:229–236
  14. Reig M, Moreno A, Baquero F. Resistance of Peptostreptococcus spp. to macrolides and lincosamides: inducible and constitutive phenotypes. Antimicrob Agents Chemother. 1992;36:662–664
  15. Pankuch GA, Jacobs MR, Appelbaum PC. Susceptibilities of 428 Gram-positive and -negative anaerobic bacteria to Bay y3118 compared with their susceptibilities to ciprofloxacin, clindamycin, metronidazole, piperacillin, piperacillin–tazobactam, and cefoxitin. Antimicrob Agents Chemother. 1993;37:1649–1654
  16. Sanchez ML, Jones RN, Croco JL. Use of the E-test to assess macrolide–lincosamide resistance patterns among Peptostreptococcus species. Antimicrob Newslett. 1992;8:45–52
  17. Wybo I, Pierard D, Verschraegen I, Reynders M, Vandoorslaer K, Claeys G, et al. Third Belgian multicentre survey of antibiotic susceptibility of anaerobic bacteria. J Antimicrob Chemother. 2007;59:132–139
  18. Kononen E, Bryk A, Niemi P, Kanervo-Nordstrom A. Antimicrobial susceptibilities of Peptostreptococcus anaerobius and the newly described Peptostreptococcus stomatis isolated from various human sources. Antimicrob Agents Chemother. 2007;51:2205–2207
  19. Reig M, Baquero F. Antibacterial activity of clavulanate and tazobactam on Peptostreptococcus spp.. J Antimicrob Chemother. 1994;33:358–359
  20. Garcia-Rodriguez JA, Garcia-Sanchez JE, Munoz-Bellido JL. Antimicrobial resistance in anaerobic bacteria: current situation. Anaerobe. 1995;1:69–80
  21. Wildeboer-Veloo AC, Harmsen HJ, Welling GW, Degener JE. Development of 16S rRNA-based probes for the identification of Gram-positive anaerobic cocci isolated from human clinical specimens. Clin Microbiol Infect. 2007;13:985–992
  22. Hecht DW. Anaerobes: antibiotic resistance, clinical significance, and the role of susceptibility testing. Anaerobe. 2006;12:115–121
  23. Hecht DW. Prevalence of antibiotic resistance in anaerobic bacteria: worrisome developments. Clin Infect Dis. 2004;39:92–97

PII: S0924-8579(07)00578-X

doi: 10.1016/j.ijantimicag.2007.11.006

International Journal of Antimicrobial Agents
Volume 31, Issue 4 , Pages 316-320 , April 2008

Article Tools